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Chapter 22
Assessment of AMPK-Stimulated Cellular Long-Chain Fatty
Acid and Glucose Uptake
Joost J. F. P. Luiken, Dietbert Neumann, Jan F. C. Glatz, Will A. Coumans,
Dipanjan Chanda, and Miranda Nabben
Abstract
Here we describe an assay for simultaneous measurement of cellular uptake rates of long-chain fatty acids
(LCFA) and glucose that can be applied to cells in suspension. The uptake assay includes the use of
radiolabeled substrates at such concentrations and incubation periods that exact information is provided
about unidirectional uptakes rates. Cellular uptake of both substrates is under regulation of AMPK. The
underlying mechanism includes the translocation of LCFA and glucose transporters from intracellular
membrane compartments to the cell surface, leading to an increase in substrate uptake. In this chapter,
we explain the principles of the uptake assay before detailing the exact procedure. We also provide
information of the specific LCFA and glucose transporters subject to AMPK-mediated subcellular translo-
cation. Finally, we discuss the application of AMPK inhibitors and activators in combination with cellular
substrate uptake assays.
Key words Long-chain fatty acid uptake, Glucose uptake, Initial uptake rate, AMPK inhibitors,
AMPK stimuli, CD36 translocation, GLUT4 translocation
1 Introduction
For the majority of mammalian cell types, LCFA and glucose are
the most important substrates for cellular energy production. But
in order to serve as energy source, both substrates need to be taken
up across the plasma membrane. In the remainder of this chapter,
we focus on cardiomyocytes, but the general principles of the
cellular uptake process are likely to apply to most other mammalian
cell types, as has been proven for skeletal muscle cells, adipocytes,
hepatocytes, enterocytes, etc. Notably, as observed in cardiomyo-
cytes and skeletal muscle cells, the crossing of the plasma membrane
presents the rate-limiting step in the cellular metabolism of both
substrates [1–3]. Once inside the cells, both substrates can be
readily oxidized according to the metabolic needs of the cells but
also stored in times of plenty. Based on its lipophobic properties,
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glucose does not readily cross the plasma membrane, and mem-
brane transporters have long been recognized to mediate the bulk
of glucose uptake [4]. These transporters are mainly members of
the GLUT family: integral membrane proteins that contain 12 -
membrane-spanning helices. In contrast, due to their lipophilic
properties, LCFA have been postulated to cross the plasma mem-
brane solely via passive diffusion [5, 6]. Only in the late 1980s of
the previous century, transporters emerged as key mediators of bulk
LCFA uptake (e.g., see [7]). The latter notion followed from several
lines of kinetic evidence, including saturation of cellular LCFA
uptake (Fig. 1), and sensitivity to competitive substrates and to
inhibitors of protein-mediated membrane transport [2]. However,
LCFA uptake also displays a non-saturable component, which at
physiological LCFA concentrations contributes only modestly to
the uptake process, but increases in relative contribution at exceed-
ingly high nonphysiological concentrations [7]. The uptake proce-
dure described below is carried out at low and physiological LCFA
concentrations as measured in human plasma [8].
Fig. 1 Kinetics of palmitate uptake and utilization in rat cardiomyocytes. (a) Time course of palmitate uptake
and utilization. Cardiomyocytes were incubated with palmitate bound to BSA at final concentrations of 90 and
300 μM, respectively (palmitate/BSA molar ratio 0.3), and analyzed at the indicated time points on cellular
uptake of palmitate ( filled circle) and formation of CO2 ( filled triangle). (b) Palmitate uptake as function of the
exogenous palmitate concentration. Cardiomyocytes were incubated with varying concentrations of palmitate
bound to BSA (final BSA concentration 300 μM) resulting in palmitate/BSA molar ratios ranging from 0 to
5. Cellular uptake of palmitate was determined at 3 min after substrate addition. In the inset, palmitate uptake
is plotted against the unbound palmitate concentration, which is calculated from the palmitate/BSA molar ratio
[14]. This figure is modified from Ref. [8]
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1.1 Considerations
of the Uptake Assay
1.1.1 Applicability
This protocol of measurement of cellular substrate uptake is dedi-
cated to primary cells in suspension and is suitable for investigation
of the short-term regulation of substrate uptake. Working with
primary cells in suspension has the advantage to prevent major
cell loss accompanying their maintenance in culture. When one is
interested in long-term regulation of substrate uptake, as exerted
by transcription factors and subsequent de novo synthesis of sub-
strate transporters, use of primary cells attached to laminin-coated
wells is a more appropriate model of study. In that case, we advise to
use a modified version of this uptake protocol [9]. On the other
hand, cultured cells can be detached from their plates and undergo
the uptake protocol as described below.
1.1.2 Radioactive
Tracers
The most sensitive method to measure substrate uptake is via
radioactive tracers. Uptake is measured as cell-associated radioac-
tivity, which can be determined upon centrifugation and
subsequent washing of the cells after a fixed time of incubation
with the radioactive substrates. The most commonly used LCFA
tracer is [1-14C]palmitate, but also [14C] or [3H] derivatives of
oleate are often used, although these have the disadvantage of
being considerably more expensive. The radiolabeled LCFA will
be taken up into the cells mainly via LCFA transporters. Thereafter,
they are intracellularly transported by small cytoplasmic fatty acid-
binding proteins (FABP) to the cytoplasmic leaflet of the outer
mitochondrial membrane for conversion into CoA esters by fatty
acyl-CoA synthetase. This activation is needed for further metabo-
lism, being oxidation within mitochondria, storage as triacylglycer-
ols within lipid droplets and/or conversion into various other lipid
species [3]. Depending on cell type and metabolic state, a variable
portion of the fatty acyl-CoA will be destined for β-oxidation.
Importantly, palmitate uptake needs to be measured during the
initial uptake phase, when substrate uptake kinetics proceeds linear
with time. Namely, beyond the initial uptake phase, efflux of the
14C-label will gradually increase as a result of equilibration of
[1-14C]palmitate with the endogenous non-labeled palmitate
pools [8]. Hence, during the initial uptake phase, measurement of
uptake provides unbiased information on unidirectional influx of
palmitate. Another reason for a rapid measurement of palmitate
uptake relates to a progressive loss of 14C-label due to β-oxidation.
Specifically using [1-14C]palmitate, the 14C-label at the C1 posi-
tion will already disappear within the first round of β-oxidation,
yielding a radioactive acetyl-CoA and a non-labeled myristoyl-CoA,
of which the latter can no longer be traced. The radiolabeled acetyl-
CoA subsequently enters the TCA cycle leading to 14CO2 produc-
tion. This CO2 diffuses away from the cells and the liquid medium
into the gas phase. Hence, the portion of 14CO2 produced from
[1-14C]palmitate escapes the radioactive detection and leads to
underestimation of the uptake rates. In metabolically active primary
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cardiomyocytes, this initial uptake phase amounts to 3–5 min after
addition of the radiolabeled substrates (Fig. 1a) [8]. In most cardiac
cell lines, the initial uptake rate is lower compared to primary
cardiomyocytes and in the linear phase for up to 30 min [9, 10].
To obtain information about cellular glucose uptake,
non-metabolizable glucose analogs such as radiolabeled
2-deoxyglucose (2-deoxy-D-[3H]glucose) are often applied, so
that glucose uptake can be assessed independently of metabolism.
Glucose and 2-deoxyglucose display similar uptake kinetics in car-
diomyocytes (Luiken, unpublished). Whereas glucose is mostly
used in uptake studies at physiological millimolar concentrations,
it is advisable to use 2-deoxyglucose at submillimolar concentra-
tions in order to minimize undesirable accumulation of 2-deoxy-
glucose-6-phosphate. The use of non-metabolizable analogs would
also be advantageous for LCFA uptake studies. Yet,
non-metabolizable LCFA analogs as 2-bromopalmitate [11] dis-
play much slower uptake rates due to the bulky bromo group and
therefore do not reflect their naturally occurring counterparts. For
the same reason, also iodo-fatty acids would display nonphysiolo-
gically low uptake rates. These iodo-fatty acids (e.g., 15-(p-iodo-
phenyl)3(R,S)-methylpentadecanoic acid) are, however, suitable
for PET imaging of myocardial metabolism [12].
1.1.3 LCFA-Albumin
Ratios
Another complication with respect to measuring LCFA uptake is
that this substrate is virtually insoluble in aqueous solutions
[13]. In the mammalian circulation, LCFA are almost completely
bound to albumin. In most cellular systems, high-affinity albumin
binding sites have been found, which brings the LCFA-albumin
complex in close proximity to the plasma membrane. Subsequently,
the LCFA gain access to their membrane transporters. Hence, the
cellular uptake of LCFA from the LCFA-albumin complex is an
entire protein-mediated process. Conversely, dissolving radiola-
beled LCFA in lipophilic solvents, such as DMSO, would lead to
the partitioning of LCFA into the outer plasma membrane mono-
layer rather than being taken up by a physiological process involv-
ing membrane-binding proteins. Albumin has 6–8 binding sites for
LCFA.When palmitate will be mixed with albumin at ratios exceed-
ing 8:1, palmitate micelles will be formed. Such micelles will readily
incorporate into membranes so that nonphysiologically high
uptake rates will be recorded. An important point of consideration
is that palmitate is taken up as a function of the “free,” i.e., non-
albumin-bound palmitate concentration and not the total palmitate
concentration [8]. At least in media with albumin concentrations
>4 μM, the free palmitate concentration is entirely governed by the
palmitate-albumin ratio [14]. Therefore in studies on fatty acid
uptake regulation, the respective Materials and Methods sections
(describing the uptake assay) should detail not only the total LCFA
concentration but also the LCFA-albumin ratio. The physiological
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LCFA-albumin ratio roughly varies between 0.3 and 3. Of further
note, possible changes in LCFA uptake would be most sensitively
detected at palmitate-albumin ratios well below the ratio at which
the rate is half of Vmax, thus reflecting an apparentKm (in analogy to
Michaelis-Menten kinetics of enzyme reactions). As an example, in
cardiomyocytes, palmitate-albumin ratios should be used below a
ratio of 1.45, which amounts to the apparent Km of palmitate
uptake in this cell type (Fig. 1b) [8].
1.1.4 Stop Procedures Several stop procedures have been applied to terminate the uptake
process, for instance, centrifugation of the cells through a layer of
silicon oil [5]. This latter stop protocol can be applied to primary
hepatocytes but is not suited for every cell type. For studies with
cardiomyocytes, we have adopted a stop procedure from Sorrentino
et al. [7]. This method brings together three different means con-
tributing to stop radiolabeled substrate uptake: (1) dilution with
excess cold substrate, (2) removal of LCFA that are loosely attached
to the outer leaflet of the plasma membrane (but have not been
taken up) by inclusion of albumin in the stop buffer, and (3) addi-
tion of phloretin, a nonselective inhibitor of carrier-mediated mem-
brane transport processes [15].
1.1.5 Limitations The substrate uptake rates to be calculated from these single-cell
suspensions will definitely differ from the in vivo uptake rates,
because the cells are incubated in the absence of blood-delivered
hormonal and any mechanical stimuli. In primary culture, cardio-
myocytes are not stimulated to contract and, at the most, will
display some irregular spontaneous contractions. But these occa-
sional contractions do not compare with the metabolic demands of
the in vivo contractions. Hence, in vitro uptake rates are expected
to be at least a magnitude lower. But nonetheless, single-cell sus-
pensions offer the opportunity to investigate the kinetics and influ-





The described protocol of cellular substrate uptake is designed for
cells in suspension, which can be maintained in viable shape for
periods up to 2 h. Hence only short-term regulation of substrate
uptake by AMPK needs to be taken into account. Theoretically
these would include posttranslational modification (e.g., phosphor-
ylation) of substrate transporters or, alternatively, translocation of
substrate transporters from intracellular stores to the plasma mem-
brane. In particular, there is a wealth of evidence that AMPK
modulates substrate uptake through the translocation of substrate
transporters [3, 16, 17].
With respect to glucose uptake, mostly GLUT1 and GLUT4
have been investigated in relation to AMPK. Whereas AMPK regu-
lation of GLUT1 has been reported to occur via direct activation at
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the plasma membrane in clone-9 cells [18], GLUT1 activity in
muscle cells is generally regarded as non-inducible, involved in
merely basal glucose uptake [19]. On the other hand, there is
ample evidence that GLUT4 translocation is the main mechanism
by which AMPK regulates changes in glucose uptake [20]. In case
of LCFA uptake, a number of structurally unrelated proteins have
been proposed to facilitate LCFA uptake. These proteins include
the peripheral membrane protein FABPpm, the channel-forming
family of the FATPs, and the scavenger receptor CD36, also
referred to as SR-B2, supposedly acting as a flippase [3]. Although
FABPpm, FATP1, and FATP4, but not FATP6, appear to translo-
cate to the cell surface upon AMPK activation in skeletal muscle
cells [21], this has not been reproduced in cardiomyocytes [22]. It
is now well established that regulation of LCFA transport by car-
diac AMPK relies entirely on the translocation of CD36 to the cell
surface, with a very similar molecular mechanism to that of
GLUT4. Of note, the same upstream and downstream signaling
components appear to be involved, thereby further reinforcing the
similarity of both translocation processes. The upstream and down-
stream mechanisms involved in AMPK-mediated GLUT4 translo-
cation have been intensively studied (e.g., see Ref. [20]). In short,
upstream of AMPK, the kinases LKB1 and CaMKK-β have been
implicated, dependent on the cell type (LKB1 in the heart and
CaMKK-β in skeletal muscle). Downstream of AMPK, AS160 is
the most important AMPK target leading to GLUT4 translocation
via de-inhibition of specific Rab proteins [23]. Remarkably, AMPK-
stimulated CD36 translocation in the heart and muscle shares the
same upstream and downstream signaling components as AMPK-
stimulated GLUT4 translocation, including LKB1, CaMKK-β, and
AS160 [24–26]. Hence the AMPK signaling pathway similarly
regulates LCFA uptake and glucose uptake.
2 Materials
2.1 Equipment 1. Shaking water bath (including temperature control and holders
for 20-mL vials).
2. Magnetic stirrer.
3. Gas phase system of 95% O2/5% CO2.
4. N2 gas.
5. Liquid scintillation counter (β-counter).
6. Glass β-counter vials.
2.2 Cells 7. Cell suspensions can be obtained as primary cells upon isolation
from rodent organs (e.g., heart) or can be derived from cell
cultures upon dis-attachment from the culture wells.
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2.3 Uptake Assay 1. Ethanol.
2. DMSO.
3. KOH: 1 M KOH.
4. CaCl2: 100 mM CaCl2.
5. Bovine serum albumin (BSA)—Fraction V (fatty acid-free).
6. Palmitic acid.
7. [1-14C]palmitate.
8. 2-Deoxyglucose/2-deoxy-D-[3H]glucose mix: 10 mM
2-deoxyglucose and 2.2 μCi 2-deoxy-D-[3H]glucose.
9. AMPK activators and/or inhibitors.
10. OPTI-FLUOR liquid scintillation cocktail.
Solutions to Be Prepared in Advance
11. 10 MKR: 1.17 M NaCl, 26 mM KCL, 12 mM KH2PO4,
12 mM MgSO4, 100 mM NaHCO3, and 100 mM HEPES,
pH 7.55. Use a 1 L glass cylinder or a glass beaker. Weigh the
indicated amount of the following chemicals: 68.36 g of NaCl,
1.94 g of KCl, 1.63 g of KH2PO4, 2.96 g of MgSO4·7H2O,
8.4 g of NaHCO3, and 23.83 g of HEPES. Add distilled H2O
to a volume of 800 mL. Mix and adjust pH to 7.55 with 1 M
NaOH. Make up to 1000 mL with distilled H2O and store at
4 C. This stock solution should be diluted in later steps to the
indicated dilutions.
12. Stock [1-14C]palmitate label: 1.8 mM palmitate complexed to
0.3 mM (≙2.0% w/v) BSA, 17.4 μM [1-14C]palmitate, and
1 mMCaCl2 in 1MKR. Prepare pre-warmed BSA solution in
a 100 mL glass cylinder, by dissolving 1.0 g of BSA in 40 mL of
1,25 MKR. Place in a shaking water bath at 37 C until
further use (100 rpm). Weigh 23.1 mg of palmitic acid in a
100 mL glass cylinder, and dissolve in 9.5 mL of pure ethanol.
Add 50 μCi of [1-14C]palmitate (see Note 1), and mix thor-
oughly. Use a 10 mL glass cylinder to prepare 10 mL of KOH
solution by pipetting 135 μL of 1 M KOH into 10 mL distilled
H2O. Add, drop by drop under constant stirring, the 10 mL of
KOH solution to the 10 mL of palmitate-ethanol solution (see
Note 2). Evaporate all ethanol at 45 C (in water bath) under a
constant stream of N2 gas until the odor of alcohol can no
longer be detected and the volume is less than 8 mL. Adjust the
volume to 10 mL with distilled H2O. Add this 10 mL
KOH-palmitate solution drop by drop with a glass pipette (see
Note 3), under continuous gentle stirring (see Note 2) to the
pre-warmed BSA solution (total volume 50 mL). Add 0.5 mL
of 100 mM CaCl2. Transfer into glass centrifuge tubes, and
spin down for 10 min at 3000  g at room temperature.
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Aliquot the supernatant into 2–5 mL portions in glass vials and
store at 20 C.
Solutions to Be Prepared Extemporaneously the Day of
Experiment
13. Uptake buffer: 1MKR, 1 mMCaCl2, and 0,45% (w/v) BSA.
Take a 100 mL glass cylinder. Add 0.23 g of BSA, 49.5 mL of
MKR buffer, and 0.5 mL of 100 mM CaCl2. Place uptake
buffer in a water bath at 37 C.
14. Day Label (for up to 20 incubations): 100 μM [1-14C]palmi-
tate, 100 μM deoxy-glucose, and 3.3 μCi 2-deoxy-D-[3H]glu-
cose. Take a 10 mL glass vial, and add 9.34 mL of uptake
buffer, 0.56 mL of Stock [1-14C]palmitate label, and 100 μL
of 10 mM 2-deoxyglucose/2-deoxy-D-[3H]glucose mix. Place
the vial in a water bath at 37 C.
15. Stop solution (for ~20 incubations): 0.2 mM phloretin and
0.1% (w/v) BSA. Prepare phloretin solution by dissolving
21.8 mg of phloretin in 400 μL DMSO. Use a 500 mL glass
cylinder, and add 400 mL of 1 MKR buffer, 4.0 mL of
100 mM CaCl2, 0.40 g of BSA (Fraction V, essentially fatty
acid-free), and the phloretin solution. For each condition,
prepare a 15-mL centrifugation tube with 8 mL Stop solution
added. Place tubes on ice.
16. Working solutions of desired AMPK stimuli (see Note 4)
and/or inhibitors (see Note 5).
3 Methods
1. Suspend cells in uptake buffer (50,000–500,000 cells/mL)
(depending on metabolic activity of cells; see Notes 6 and 7),
and distribute over (20-mL) glass vials. Add 2 mL of cell
suspension per vial.
2. Preincubate the cell suspension at 37 C with a gas phase of
95% O2 /5% CO2 with inhibitors of AMPK for 20 min in a
water bath (shaking at 160 rpm).
3. Subsequently, add activators of AMPK, refill the gas phase, and
incubate for another 30 min at 37 C.
4. Start the uptake assay by adding 0.5 mL of Day Label to the cell
suspension, and incubate for 5 min at 37 C in a water bath
with a gas phase of 95% O2/5% CO2. Each cellular substrate
uptake assay should include a “zero time control” to allow to
correct for the background signal (see Note 8).
5. After 5 min, stop the assay, and transfer 2 mL of cell suspension
from each incubation to centrifugation tubes with 8 mL of
ice-cold Stop solution.
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6. Spin the cells down for 2 min at 4 C (see Note 9). Remove
the supernatant and wash with 10mL of ice-cold Stop solution.
Repeat the centrifugation step.
7. Lyse the pellets in 0.5 mL of distilled H2O, and transfer the
lysates to 20 mL glass β-counter vials containing 5 mL of
OPTI-FLUOR liquid scintillation cocktail. Do not forget to
include a sample with a fixed volume (e.g., 20 μL) of Day Label
for scintillation counting in order to allow for calculation of
absolute uptake rates.
8. Vortex the samples, and measure the disintegration counts per
minute at the β-counter using a combined 3H/14C counting
protocol.Uptakevaluesareexpressedasnmol/(gwetmass*min),
after subtracting the background signal (seeNote 8). A represen-
tative data set of a substrate uptake assay using AMPK activators is
given in Table 1.
4 Notes
1. It is advised to purchase and use a radiolabeled palmitate prod-
uct dissolved in ethanol, and not toluene, because toluene is
extremely toxic to cells.
2. If precipitate is formed, discard the solution and start again.
3. Work as much as possible with glassware because (radiolabeled)
palmitate binds non-specifically to plastic surfaces. In the
uptake assay, this can lead to high background counts.
4. For selecting the appropriate AMPK activators to be used in the
intended experiments, at least the following five items are
relevant: (1) the cellular uptake process of interest, (2) the
tissue of interest from which primary cells will be isolated,
(3) the type of physiological process one aims to mimic or
investigate, (4) the off-target actions of selected compound,
and (5) the toxic effects of selected compound depending on
the cell type.
An increasing number of pharmacological AMPK activators
have been employed for the study of AMPK activation on
cellular LCFA and glucose uptake. We provide here with
some tips and consideration about the most commonly used
compounds to investigate substrate uptake in muscle cells:
– Oligomycin: It is a very potent stimulator of glucose and
LCFA uptake in primary cardiomyocytes and in cardiac cell
lines in which the uptake of both substrates increases by
~twofold already within 15–30 min [16]. It is of note that
the concentration of oligomycin tolerated by cells differs
among cell types. In cardiomyocytes, oligomycin can be
used at concentrations of up to 30 μM, but this
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concentration is cytotoxic in cell lines, such as HL-1 cells, in
which concentrations of up to 1 μM are more advisable.
Importantly, besides activation of AMPK [16], oligomycin
also stimulates production of reactive oxygen species and
subsequent activation of protein kinase-D1, another crucial
player in oligomycin-induced GLUT4 translocation and
cellular glucose uptake [27].
– Mitochondrial inhibitors: Uncoupling agents (such as
2,4-dinitrophenol) and respiratory chain inhibitors (rote-
none) stimulate cellular glucose uptake in adipocytes and
myocytes [28, 29]. However, these agents cannot be used to
study cellular LCFA uptake. Unlike glucose uptake, LCFA
uptake across the plasma membrane is dependent on the
cellular membrane potential [30], which is destroyed by
these agents since their protonophore activity is not
restricted to mitochondria [28, 31]. The respiratory chain
inhibitor rotenone potently impairs the oxidative metabo-
lism of both substrates. Because uptake and subsequent
metabolism are tightly coupled processes, the block in oxi-
dative phosphorylation leads to feedback inhibition of the
LCFA uptake process [8]. In contrast, the acceleration of
glucose uptake upon rotenone-induced AMPK activation
may be accommodated for by a concomitant acceleration
in glycolysis so that all incoming glucose is efficiently phos-
phorylated and feedback inhibition will not occur. In case of
specific interest in AMPK-stimulated glucose uptake, DNP
and rotenone should preferably be used at low micromolar
concentrations.
– AICAR: One point of concern with the use of AICAR is the
increasing list of AMPK-independent actions of AICAR
[32]. Nonetheless, AICAR has been used as activator of
LCFA uptake in skeletal muscle [33] and glucose uptake in
adipocytes [29] and skeletal muscle [34]. In cardiomyo-
cytes, AICAR, at low millimolar concentrations, stimulates
LCFA uptake by ~1.5-fold in an AMPK-dependent fashion
[25, 35], but this compound is not effective in stimulation
of GLUT4 translocation and cellular glucose uptake
(Fig. 2b) [25, 35, 36]. Thus it appears that the stimulation
of cellular glucose uptake by AICAR is tissue-specific and
should be taken into consideration when studying the
effects of AMPK activation on substrate uptake.
– Metformin and phenformin: Although these antidiabetic
drugs are known to activate AMPK at low millimolar con-
centrations [37, 38], they failed to increase GLUT4 or
CD36 translocation or cellular uptake of LCFA and glucose
within 30 min in cardiomyocytes [39] (Luiken, unpub-
lished). However, metformin has been shown to stimulate
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GLUT4 translocation in cardiomyocytes upon long-term
(18 h) treatment, indicating reliance on synthesis of specific
proteins. These proteins might be involved in the negative
regulation of GLUT4 endocytosis [39].
Fig. 2 Effects of Compound C on substrate uptake into rat cardiomyocytes stimulated by various AMPK
activators. Cell suspensions were incubated in absence or presence of 50 μM Compound C for 30 min, and
subsequently for another 15 min without or with 5 μM oligomycin or 1.5 mM AICAR. Alternatively,
electrostimulation was performed for 7 min at 4 Hz. Then, radioactive substrates were added for
measurement of (a) palmitate uptake or (b) deoxyglucose uptake during 5 min. Data are means  S.E.M
(n ¼ 4–6). *Significantly different from myocytes without additions (Ctrl) ( p < 0.05). ^Significantly different
from corresponding incubations in the absence of Compound C (Basal) ( p < 0.05)
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– Small-molecule direct AMPK activators: A screen by the
Abbott Laboratories of >700,000 compounds yielded a
non-nucleoside thienopyridone, A-769662, as novel small-
molecule AMPK activator [40]. In skeletal muscle strips, it
appeared ineffective on stimulation of glucose uptake
[41]. In cardiomyocytes at concentrations between 30 and
300 μM, during 30 min, it also failed to stimulate AMPK-
Thr172 phosphorylation or LCFA and glucose uptake
(Habets and Luiken, unpublished). Compared with β1-con-
taining heterotrimers, β2-containing AMPK isoforms are
less efficiently activated by A-769662 [42]. Given that mus-
cle tissues mainly express the AMPK β2 subunit isoform,
A-769662 may be a less favorable option for studying the
role of AMPK in the heart and skeletal muscle.
More recently, another small-molecule AMPK activator,
991 (also known as ex229), has been described
[41]. Although it shares the same binding site on AMPK
as A-769662, it showed a ~tenfold greater potency to acti-
vate AMPK [43]. Interestingly, 991 activates both AMPK
β1- and β2-containing complexes and efficiently stimulates
glucose uptake into skeletal muscle at 100 μM for 60 min
[41]. Further studies are required to investigate whether
this compound is a suitable tool to study substrate uptake
in cardiac cells.
– Leptin: This hormone is a physiological AMPK activator and
stimulates CD36 translocation in an AMPK-dependent
manner at 10 μg/mL for 15–60 min, as well as LCFA
uptake in skeletal muscle incubations and cardiomyocytes
[44]. With respect to glucose uptake, 20 min leptin was
ineffective in stimulating glucose uptake in HL-1 cardio-
myocytes [45]. In contrast, 30 min leptin stimulates
GLUT4 translocation in C2C12 myotubes, which was
dependent on ERK2 [46] and perhaps independent of
AMPK. Hence, a pleiotropy of stimulatory actions on intra-
cellular signaling cascades makes leptin less suited as a tool
to study AMPK-specific regulation of substrate uptake.
5. Genetic approaches would be the preferable manner to investi-
gate the involvement of AMPK in substrate uptake. An excel-
lent option would be to use primary cells from tissues derived
from AMPK knockout mouse models for assessment of cellular
substrate uptake. But since at least two isoforms of the catalytic
α and regulatory β subunits are expressed in mammals, one
needs double-knockout mouse models for these subunits to
provide full proof for the involvement of AMPK. But in case
that one is only interested in the role of AMPK in a specific
tissue, a single-knockout mouse will suffice, when the respec-
tive tissue only expresses one isoform. For example, in muscle
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tissues, AMPKα2 knockout mice would be suitable, given that
the α1 subunit is only marginally expressed in muscles. Fur-
thermore, the muscle-specific kinase-dead AMPKα2 overex-
pressing mouse [47] provides a very suitable model for the
role of AMPK in muscles. A second option would be to silence
AMPK in cell lines, e.g., by siRNA approach or CRISPR/Cas9
(see Chapter 11). However, when AMPK mouse models or
silencing methodologies are not available, one can consider a
pharmacological approach and use small-molecule AMPK inhi-
bitors. Below is a list of compounds previously used in substrate
uptake studies:
– 5-Iodotubercidin: 5-Iodotubercidin is not a direct AMPK
inhibitor but blocks the formation of AMP from adenosine
via inhibition of adenosine kinase [48]. Treatment with
5-iodotubercidin for 10 μM at 15–30 min blocks AICAR-
induced LCFA uptake into cardiomyocytes [16] and glu-
cose uptake into clone-9 cells [18] and muscle strips [49], in
agreement with its ability to inhibit ZMP formation. In
contrast, 5-iodotubercidin does not alter contraction and
oligomycin-stimulated LCFA uptake into cardiomyocytes
[16], which is readily explained by the fact that AMP forma-
tion due to stress or increased energy demands is derived
from ATP utilization and not from AMP synthesis. Hence,
5-iodotubercidin is of limited use to study AMPK actions.
– Adenine 9-β-D-arabinofuranoside (Ara-A): This AMP ana-
log decreases AMPK activity in vitro [50]. Ara-A is used in
concentrations of 2–3 mM for 15–30 min and entirely
inhibits AICAR-induced glucose uptake into muscle strips
[49]. It also inhibits stimulation of GLUT4 translocation
and glucose uptake in neonatal cardiomyocytes by respira-
tory chain inhibition using sodium azide (NaN3). Further-
more, Ara-A inhibits AICAR-stimulated LCFA uptake into
primary cardiomyocytes [35] and also leptin-stimulated
CD36 translocation and LCFA uptake into skeletal muscle
and primary cardiomyocytes [44]. Hence, as AMPK inhibi-
tor, Ara-A has a broader applicability than 5-iodotubercidin
in studying AMPK-related actions but has also numerous
other inhibitory effects, such as inhibition of adenylyl
cyclase [51].
– Compound C: As selected from a high-throughput in vitro
kinase assay out of >10.000 compounds, Compound C
appeared a potent reversible AMPK antagonist via competi-
tion with ATP [37]. Compound C is mostly used in con-
centrations of 10–50 μM and has been shown to inhibit
AICAR-induced GLUT4 translocation [52] and AICAR-
stimulated glucose uptake [53]. We have used Compound
C (50 μM) to study AMPK-mediated LCFA and glucose
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uptake into primary cardiomyocytes. AICAR-stimulated
LCFA uptake was entirely inhibited, whereas contraction
and oligomycin-stimulated LCFA uptake were not signifi-
cantly altered (Fig. 2a). This inhibition pattern does not
match with the presumed direct action of Compound C
on AMPK. Furthermore, interpretation of the effects of
Compound C on AMPK-stimulated glucose uptake was
complicated by a large effect of this inhibitor on basal glu-
cose uptake (Fig. 2b), in agreement with Merlin et al.
[53]. Please note that AICAR does not stimulate glucose
uptake into rodent cardiomyocytes (Fig. 2b). Finally, the list
of off-target actions of Compound C on other kinases, such
as ERK8 and MNK1, is growing [54]. As described in
Chapter 12, there are serious doubts about the specificity
of Compound C and whether it is a useful tool for
studying AMPK.
– STO-609: STO-609 does not inhibit AMPK directly but
rather blocks upstream activation. Specifically, STO-609 is
an antagonist of Ca2+/calmodulin-dependent kinase kinase
(CaMKK) [55]. Together with liver kinase B1 (LKB1) and
transforming growth factor beta-activated kinase 1 (TAK1)
[56], CaMKK-β is one of the several kinases able to directly
activate AMPK. Hence, STO-609 is of no use to study
activation of AMPK by LKB1 and TAK1. Given that most
inflammatory stimuli act via TAK1 and given that LKB1 is
the major upstream activator of AMPK in several tissues,
including the heart [25], STO-609 is often of limited use in
AMPK research. We observed that STO-609 (5 μM;
20 min) does not block LCFA and glucose uptake stimu-
lated by oligomycin or AICAR [35].
But still, STO-609 may be a suitable tool to connect Ca2+
signaling to AMPK signaling. In skeletal muscle, the Ca2+
signaling activator caffeine stimulates AMPKα2 activation,
and also LCFA and glucose uptake. Moreover, LCFA and
glucose uptake stimulated by contraction or caffeine is
largely blocked by STO-609 indicating an important role
of CaMKK-β in AMPK regulation of substrate uptake in
contracting muscle [24]. In contrast STO-609 did not
inhibit contraction-stimulated LCFA and glucose uptake
into primary cardiomyocytes, pinpointing to a less promi-
nent role of Ca2+ signaling in contraction-regulated metab-
olism in the heart [35].
6. The isolation procedure raises cellular stress levels, and primary
cells should preferably undergo a recovery period of ~90 min at
room temperature after their isolation to allow the metabolic
rate to decrease to low “basal” levels. In case of cultured cells, a
~60 min recovery period is recommended after the
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dis-attachment from the plates with a low trypsin concentra-
tion (0.05%) to minimize damage to exposed substrate trans-
porters at the cell surface.
7. Most primary cells can be regarded as metabolically active cells,
especially since isolation procedures have been optimized for
many years. When these cells are immediately used for substrate
uptake assays, their metabolic activity will be highest, likely
resulting in relatively high substrate uptake rates. Culturing of
primary cells leads to a marked decline in metabolic activity
depending on the duration and culturing conditions. Upon
their dis-attachment from the culture wells, it is therefore
recommended to use higher cell densities in the uptake assay,
compared to their freshly used counterparts. Lowest metabolic
activity is displayed by the cell lines and likely dependent on the
number of passages. Therefore, relatively high cell densities
should be used in order to obtain accurately detectable uptake
values. Overall, it is recommended to perform a pilot measure-
ment of substrate uptake as function of the cell density.
8. Correction for background signal: At least one incubation per
experiment should serve as “zero time control” (t ¼ 0). In this
case, the cell suspension (1.6 mL) should be transferred to the
Stop solution prior to addition of the Day Label (0.4 mL). The
remainder of the procedure is similar as described for the other
incubations. When performing the calculation of uptake rates,
the counts of this “zero time control” should be subtracted
from the radioactive counts of each incubation.
9. The centrifugation speed is dependent on the size of the cells
(e.g., primary cardiomyocytes are pelleted at 25 g; several cell
lines require centrifugation speeds of ~1000  g).
References
1. Shulman GI (2000) Cellular mechanisms of
insulin resistance. J Clin Invest 106
(2):171–176. https://doi.org/10.1172/
JCI10583
2. Luiken JJ, Schaap FG, van Nieuwenhoven FA,
van der Vusse GJ, Bonen A, Glatz JF (1999)
Cellular fatty acid transport in heart and skele-
tal muscle as facilitated by proteins. Lipids 34
(Suppl):S169–S175
3. Glatz JF, Luiken JJ, Bonen A (2010) Mem-
brane fatty acid transporters as regulators of
lipid metabolism: implications for metabolic
disease. Physiol Rev 90(1):367–417. https://
doi.org/10.1152/physrev.00003.2009
4. Mueckler M (1994) Facilitative glucose trans-
porters. Eur J Biochem 219(3):713–725
5. Rose H, Hennecke T, Kammermeier H (1990)
Sarcolemmal fatty acid transfer in isolated car-
diomyocytes governed by albumin/mem-
brane-lipid partition. J Mol Cell Cardiol 22
(8):883–892
6. Hamilton JA, Johnson RA, Corkey B, Kamp F
(2001) Fatty acid transport: the diffusion
mechanism in model and biological mem-
branes. J Mol Neurosci 16(2–3):99–108.; dis-
cussion 151–157. https://doi.org/10.1385/
JMN:16:2-3:99
7. Sorrentino D, Stump D, Potter BJ, Robinson
RB, White R, Kiang CL, Berk PD (1988) Ole-
ate uptake by cardiac myocytes is carrier
mediated and involves a 40-kD plasma mem-
brane fatty acid binding protein similar to that
in liver, adipose tissue, and gut. J Clin Invest 82




8. Luiken JJ, van Nieuwenhoven FA, America G,
van der Vusse GJ, Glatz JF (1997) Uptake and
metabolism of palmitate by isolated cardiac
myocytes from adult rats: involvement of sar-
colemmal proteins. J Lipid Res 38(4):745–758
9. Schwenk RW, Dirkx E, Coumans WA,
Bonen A, Klip A, Glatz JF, Luiken JJ (2010)
Requirement for distinct vesicle-associated
membrane proteins in insulin- and
AMP-activated protein kinase (AMPK)-
induced translocation of GLUT4 and CD36
in cultured cardiomyocytes. Diabetologia 53
(10):2209–2219. https://doi.org/10.1007/
s00125-010-1832-7
10. Van Nieuwenhoven FA, Luiken JJ, De Jong
YF, Grimaldi PA, Van der Vusse GJ, Glatz JF
(1998) Stable transfection of fatty acid translo-
case (CD36) in a rat heart muscle cell line
(H9c2). J Lipid Res 39(10):2039–2047
11. Oakes ND, Kjellstedt A, Forsberg GB,
Clementz T, Camejo G, Furler SM, Kraegen
EW, Olwegard-Halvarsson M, Jenkins AB,
Ljung B (1999) Development and initial eval-
uation of a novel method for assessing tissue-
specific plasma free fatty acid utilization in vivo
using (R)-2-bromopalmitate tracer. J Lipid Res
40(6):1155–1169
12. Verberne HJ, Sloof GW, Beets AL, Murphy
AM, van Eck-Smit BL, Knapp FF (2003)
125I-BMIPP and 18F-FDG uptake in a trans-
genic mouse model of stunned myocardium.
Eur J Nucl Med Mol Imaging 30(3):431–439
13. Vorum H, Brodersen R, Kragh-Hansen U,
Pedersen AO (1992) Solubility of long-chain
fatty acids in phosphate buffer at pH 7.4. Bio-
chim Biophys Acta 1126(2):135–142
14. Richieri GV, Ogata RT, Kleinfeld AM (1994)
Equilibrium constants for the binding of fatty
acids with fatty acid-binding proteins from adi-
pocyte, intestine, heart, and liver measured
with the fluorescent probe ADIFAB. J Biol
Chem 269(39):23918–23930
15. Andersen BL, Tarpley HT, Regen DM (1978)
Characterization of beta-hydroxybutyrate
transport in rat erythrocytes and thymocytes.
Biochim Biophys Acta 508(3):525–538
16. Luiken JJ, Coort SL, Willems J, Coumans WA,
Bonen A, van der Vusse GJ, Glatz JF (2003)
Contraction-induced fatty acid translocase/
CD36 translocation in rat cardiac myocytes is
mediated through AMP-activated protein
kinase signaling. Diabetes 52(7):1627–1634
17. Klip A, Schertzer JD, Bilan PJ, Thong F, Anto-
nescu C (2009) Regulation of glucose trans-
porter 4 traffic by energy deprivation from
mitochondrial compromise. Acta Physiol
(Oxf) 196(1):27–35. https://doi.org/10.
1111/j.1748-1716.2009.01974.x
18. Abbud W, Habinowski S, Zhang JZ,
Kendrew J, Elkairi FS, Kemp BE, Witters LA,
Ismail-Beigi F (2000) Stimulation of
AMP-activated protein kinase (AMPK) is asso-
ciated with enhancement of Glut1-mediated
glucose transport. Arch Biochem Biophys 380
(2):347–352. https://doi.org/10.1006/abbi.
2000.1935
19. Abel ED (2004) Glucose transport in the
heart. Front Biosci 9:201–215
20. Richter EA, Hargreaves M (2013) Exercise,
GLUT4, and skeletal muscle glucose uptake.
Physiol Rev 93(3):993–1017. https://doi.
org/10.1152/physrev.00038.2012
21. Jain SS, Chabowski A, Snook LA, Schwenk
RW, Glatz JF, Luiken JJ, Bonen A (2009)
Additive effects of insulin and muscle contrac-
tion on fatty acid transport and fatty acid trans-
porters, FAT/CD36, FABPpm, FATP1, 4 and
6. FEBS Lett 583(13):2294–2300. https://
doi.org/10.1016/j.febslet.2009.06.020
22. Habets DD (2008) Thesis: “Regulation of car-
diac long-chain fatty acid and glucose utiliza-
tion. Studies with cardiomyocytes from
genetically manipulated mice” Thesis
Chapter 5: AICAR stimulates long-chain fatty
acid uptake and oxidation in mouse heart inde-
pendent of CD36
23. Thong FS, Bilan PJ, Klip A (2007) The Rab
GTPase-activating protein AS160 integrates
Akt, protein kinase C, and AMP-activated pro-
tein kinase signals regulating GLUT4 traffic.
Diabetes 56(2):414–423. https://doi.org/10.
2337/db06-0900
24. Abbott MJ, Edelman AM, Turcotte LP (2009)
CaMKK is an upstream signal of
AMP-activated protein kinase in regulation of
substrate metabolism in contracting skeletal
muscle. Am J Physiol Regul Integr Comp
Physiol 297(6):R1724–R1732. https://doi.
org/10.1152/ajpregu.00179.2009
25. Habets DD, Coumans WA, El Hasnaoui M,
Zarrinpashneh E, Bertrand L, Viollet B,
Kiens B, Jensen TE, Richter EA, Bonen A,
Glatz JF, Luiken JJ (2009) Crucial role for
LKB1 to AMPKalpha2 axis in the regulation
of CD36-mediated long-chain fatty acid
uptake into cardiomyocytes. Biochim Biophys
Acta 1791(3):212–219. https://doi.org/10.
1016/j.bbalip.2008.12.009
26. Samovski D, Su X, Xu Y, Abumrad NA, Stahl
PD (2012) Insulin and AMPK regulate FA
translocase/CD36 plasma membrane recruit-
ment in cardiomyocytes via Rab GAP AS160
and Rab8a Rab GTPase. J Lipid Res 53




27. Luiken JJ, Glatz JF, Neumann D (2015) Car-
diac contraction-induced GLUT4 transloca-
tion requires dual signaling input. Trends
Endocrinol Metab 26(8):404–410. https://
doi.org/10.1016/j.tem.2015.06.002
28. Luiken JJ, Coort SL, Koonen DP, van der
Horst DJ, Bonen A, Zorzano A, Glatz JF
(2004) Regulation of cardiac long-chain fatty
acid and glucose uptake by translocation of
substrate transporters. Pflugers Arch 448
(1):1–15. https://doi.org/10.1007/s00424-
003-1199-4
29. Yamaguchi S, Katahira H, Ozawa S,
Nakamichi Y, Tanaka T, Shimoyama T,
Takahashi K, Yoshimoto K, Imaizumi MO,
Nagamatsu S, Ishida H (2005) Activators of
AMP-activated protein kinase enhance
GLUT4 translocation and its glucose transport




30. Weisiger RA, Fitz JG, Scharschmidt BF (1989)
Hepatic oleate uptake. Electrochemical driving
forces in intact rat liver. J Clin Invest 83
(2):411–420. https://doi.org/10.1172/
JCI113899
31. Park KS, Jo I, Pak K, Bae SW, RhimH, Suh SH,
Park J, Zhu H, So I, Kim KW (2002) FCCP
depolarizes plasmamembrane potential by acti-
vating proton and Na+ currents in bovine aor-
tic endothelial cells. Pflugers Arch 443
(3):344–352. https://doi.org/10.1007/
s004240100703
32. Liu X, Chhipa RR, Pooya S, Wortman M,
Yachyshin S, Chow LM, Kumar A, Zhou X,
Sun Y, Quinn B, McPherson C, Warnick RE,
Kendler A, Giri S, Poels J, Norga K, Viollet B,
Grabowski GA, Dasgupta B (2014) Discrete
mechanisms of mTOR and cell cycle regulation
by AMPK agonists independent of AMPK.
Proc Natl Acad Sci U S A 111(4):
E435–E444. https://doi.org/10.1073/pnas.
1311121111
33. Bonen A, Han XX, Habets DD, Febbraio M,
Glatz JF, Luiken JJ (2007) A null mutation in
skeletal muscle FAT/CD36 reveals its essential
role in insulin- and AICAR-stimulated fatty
acid metabolism. Am J Physiol Endocrinol
Metab 292(6):E1740–E1749. https://doi.
org/10.1152/ajpendo.00579.2006
34. Russell RR 3rd, Bergeron R, Shulman GI,
Young LH (1999) Translocation of myocardial
GLUT-4 and increased glucose uptake through
activation of AMPK by AICAR. Am J Phys 277
(2 Pt 2):H643–H649
35. Angin Y, Schwenk RW, Nergiz-Unal R,
Hoebers N, Heemskerk JW, Kuijpers MJ, Cou-
mans WA, van Zandvoort MA, Bonen A,
Neumann D, Glatz JF, Luiken JJ (2014) Cal-
cium signaling recruits substrate transporters
GLUT4 and CD36 to the sarcolemma without
increasing cardiac substrate uptake. Am J
Physiol Endocrinol Metab 307(2):
E225–E236. https://doi.org/10.1152/
ajpendo.00655.2013
36. Dirkx E, Schwenk RW, Coumans WA,
Hoebers N, Angin Y, Viollet B, Bonen A, van
Eys GJ, Glatz JF, Luiken JJ (2012) Protein
kinase D1 is essential for contraction-induced
glucose uptake but is not involved in fatty acid
uptake into cardiomyocytes. J Biol Chem 287
(8):5871–5881. https://doi.org/10.1074/
jbc.M111.281881
37. Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T,
Fujii N, Musi N, Hirshman MF, Goodyear LJ,
Moller DE (2001) Role of AMP-activated pro-
tein kinase in mechanism of metformin action.
J Clin Invest 108(8):1167–1174. https://doi.
org/10.1172/JCI13505
38. Musi N, HirshmanMF, Nygren J, Svanfeldt M,
Bavenholm P, Rooyackers O, Zhou G, Wil-
liamson JM, Ljunqvist O, Efendic S, Moller
DE, Thorell A, Goodyear LJ (2002) Metfor-
min increases AMP-activated protein kinase
activity in skeletal muscle of subjects with type
2 diabetes. Diabetes 51(7):2074–2081
39. Yang J, Holman GD (2006) Long-term met-
formin treatment stimulates cardiomyocyte
glucose transport through an AMP-activated
protein kinase-dependent reduction in
GLUT4 endocytosis. Endocrinology 147
(6):2728–2736. https://doi.org/10.1210/
en.2005-1433
40. Cool B, Zinker B, Chiou W, Kifle L, Cao N,
Perham M, Dickinson R, Adler A, Gagne G,
Iyengar R, Zhao G, Marsh K, Kym P, Jung P,
Camp HS, Frevert E (2006) Identification and
characterization of a small molecule AMPK
activator that treats key components of type
2 diabetes and the metabolic syndrome. Cell
Metab 3(6):403–416. https://doi.org/10.
1016/j.cmet.2006.05.005
41. Lai YC, Kviklyte S, Vertommen D, Lantier L,
Foretz M, Viollet B, Hallen S, Rider MH
(2014) A small-molecule benzimidazole deriv-
ative that potently activates AMPK to increase
glucose transport in skeletal muscle: compari-
son with effects of contraction and other
AMPK activators. Biochem J 460
(3):363–375. https://doi.org/10.1042/
BJ20131673
360 Joost J. F. P. Luiken et al.
d.neumann@maastrichtuniversity.nl
42. Rajamohan F, Reyes AR, Frisbie RK, Hoth LR,
Sahasrabudhe P, Magyar R, Landro JA, Withka
JM, Caspers NL, Calabrese MF, Ward J, Kur-
umbail RG (2016) Probing the enzyme kinet-
ics, allosteric modulation and activation of
alpha1- and alpha2-subunit-containing
AMP-activated protein kinase (AMPK) hetero-
trimeric complexes by pharmacological and
physiological activators. Biochem J 473
(5):581–592. https://doi.org/10.1042/
BJ20151051
43. Xiao B, Sanders MJ, Carmena D, Bright NJ,
Haire LF, Underwood E, Patel BR, Heath RB,
Walker PA, Hallen S, Giordanetto F, Martin
SR, Carling D, Gamblin SJ (2013) Structural
basis of AMPK regulation by small molecule
activators. Nat Commun 4:3017. https://doi.
org/10.1038/ncomms4017
44. Momken I, Chabowski A, Dirkx E, Nabben M,
Jain SS, McFarlan JT, Glatz JF, Luiken JJ,
Bonen A (2017) A new leptin-mediated mech-
anism for stimulating fatty acid oxidation: a
pivotal role for sarcolemmal FAT/CD36. Bio-
chem J 474(1):149–162. https://doi.org/10.
1042/BCJ20160804
45. Palanivel R, Eguchi M, Shuralyova I, Coe I,
Sweeney G (2006) Distinct effects of short-
and long-term leptin treatment on glucose




46. Berti L, Gammeltoft S (1999) Leptin stimu-
lates glucose uptake in C2C12 muscle cells by
activation of ERK2. Mol Cell Endocrinol 157
(1–2):121–130
47. Mu J, Brozinick JT Jr, Valladares O, Bucan M,
BirnbaumMJ (2001) A role for AMP-activated
protein kinase in contraction- and hypoxia-
regulated glucose transport in skeletal muscle.
Mol Cell 7(5):1085–1094
48. Samari HR, Seglen PO (1998) Inhibition of
hepatocytic autophagy by adenosine, aminoi-
midazole-4-carboxamide riboside, and
N6-mercaptopurine riboside. Evidence for
involvement of amp-activated protein kinase. J
Biol Chem 273(37):23758–23763
49. Musi N, Hayashi T, Fujii N, Hirshman MF,
Witters LA, Goodyear LJ (2001)
AMP-activated protein kinase activity and
glucose uptake in rat skeletal muscle. Am J
Physiol Endocrinol Metab 280(5):E677–E684
50. Henin N, Vincent MF, Van den Berghe G
(1996) Stimulation of rat liver AMP-activated
protein kinase by AMP analogues. Biochim
Biophys Acta 1290(2):197–203
51. Iwatsubo K, Bravo C, Uechi M, Baljinnyam E,
Nakamura T, Umemura M, Lai L, Gao S,
Yan L, Zhao X, Park M, Qiu H, Okumura S,
Iwatsubo M, Vatner DE, Vatner SF, Ishikawa Y
(2012) Prevention of heart failure in mice by an
antiviral agent that inhibits type 5 cardiac ade-
nylyl cyclase. Am J Physiol Heart Circ Physiol
302(12):H2622–H2628. https://doi.org/10.
1152/ajpheart.00190.2012
52. Niu W, Bilan PJ, Ishikura S, Schertzer JD,
Contreras-Ferrat A, Fu Z, Liu J,
Boguslavsky S, Foley KP, Liu Z, Li J, Chu G,
Panakkezhum T, Lopaschuk GD, Lavandero S,
Yao Z, Klip A (2010) Contraction-related sti-
muli regulate GLUT4 traffic in C2C12-




53. Merlin J, Evans BA, Csikasz RI, Bengtsson T,
Summers RJ, Hutchinson DS (2010) The
M3-muscarinic acetylcholine receptor stimu-
lates glucose uptake in L6 skeletal muscle cells
by a CaMKK-AMPK-dependent mechanism.
Cell Signal 22(7):1104–1113. https://doi.
org/10.1016/j.cellsig.2010.03.004
54. Vogt J, Traynor R, Sapkota GP (2011) The
specificities of small molecule inhibitors of the
TGFss and BMP pathways. Cell Signal 23
(11):1831–1842. https://doi.org/10.1016/j.
cellsig.2011.06.019
55. Tokumitsu H, Inuzuka H, Ishikawa Y,
Ikeda M, Saji I, Kobayashi R (2002)
STO-609, a specific inhibitor of the Ca(2+)/
calmodulin-dependent protein kinase kinase. J
Biol Chem 277(18):15813–15818. https://
doi.org/10.1074/jbc.M201075200
56. Witczak CA, Sharoff CG, Goodyear LJ (2008)
AMP-activated protein kinase in skeletal mus-
cle: from structure and localization to its role as
a master regulator of cellular metabolism. Cell
Mol Life Sci 65(23):3737–3755. https://doi.
org/10.1007/s00018-008-8244-6
Measuring Substrate Uptake 361
d.neumann@maastrichtuniversity.nl
